Free Trial
NASDAQ:ENGN

enGene Q2 2024 Earnings Report

enGene logo
$3.67 -0.02 (-0.54%)
Closing price 04:00 PM Eastern
Extended Trading
$3.66 -0.01 (-0.27%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

enGene EPS Results

Actual EPS
-$0.38
Consensus EPS
-$0.24
Beat/Miss
Missed by -$0.14
One Year Ago EPS
N/A

enGene Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

enGene Announcement Details

Quarter
Q2 2024
Time
N/A
Conference Call Date
Friday, June 14, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

enGene's Q2 2025 earnings is scheduled for Tuesday, June 10, 2025, with a conference call scheduled on Thursday, June 12, 2025 at 12:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

enGene Earnings Headlines

Here’s How to Claim Your Stake in Elon’s Private Company, xAI
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
See More enGene Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like enGene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on enGene and other key companies, straight to your email.

About enGene

enGene (NASDAQ:ENGN), through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

View enGene Profile

More Earnings Resources from MarketBeat